Se trataron 25 Pacientes con Esclerosis Múltiple definida, de la forma exacerbante-remitente y grados entre 1 y 5.5 en la escala de discapacidad de Kurtzke, con la Biomodulina T a la 6 ch, durante 15 meses. Al concluir el tratamiento se obtuvo un 83% de pacientes con estabilidad clínica según la escala de discapacidad. Por el efecto inmuregulador y antiinflamatario se sugiere la posibilidad de esta variante homeopática para el tratamiento de dicha enfermedad, teniendo en cuenta su bajo costo de producción y la no producción de reacciones adversas.

25 patients with defined exacerbating-remitting Multiple Sclerosis (MS), with a score between 1 and 5.5 according to Kurtzke’s disability scale, were treated with Biomoduline T at 6 ch during 15 months. After concluding this treatment 83% of the patients were clinically stable according to the disability score. Due to the immunoregulating and anti-inflammatory effects of this product, the possibility of employing this homeopathic variant for the treatment of MS is suggested, considering its low cost of production and the fact that no adverse reactions were referred.